This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bhatt, R. S. Articles by Sukhatme, V. P. Search for Related Content PubMed PubMed Citation Articles by Bhatt, R. S. Articles by Sukhatme, V. P.

Biomarkers for Monitoring Antiangiogenic Therapy

Authors' Affiliation: Divisions of Hematology-Oncology, Nephrology, Interdisciplinary Medicine, and Biotechnology, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Requests for reprints: Rupal S. Bhatt, Beth Israel Deaconess Medical Center, RW563, 330 Brookline Avenue, Boston, MA 02215. E-mail: rbhatt{at}bidmc.harvard.edu.

A variety of antiangiogenic agents are currently available for the treatment of renal cell carcinoma. With these exciting new therapeutic agents comes the challenge of elucidating useful biomarkers to monitor patients receiving these therapies. Although many patients benefit from antiangiogenic therapies, it is often by achieving stability of their disease. Thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in the management of patients. The current technologies being explored in this field include circulating plasma proteins, cells, and nucleic acids and novel imaging techniques. Surrogate markers of angiogenesis could help with selecting patients for therapy, determining optimal dosing of therapy, deciding whether to change therapy, and assessing appropriate salvage therapy.

This article has been cited by other articles:

				S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]